Study identifies path to reduce immune checkpoint inhibitor heart toxicity
A Feb. 20, 2026 study in the Journal of Experimental Medicine identified CD8 T cell-derived TNF and TNFR2 signaling as drivers of ICI-related myocarditis in mice. Blocking TNFR2 prevented the inflammatory cycle in the heart.
Scientists at Cincinnati Children’s reported discovering a way to dramatically reduce the risk that immune checkpoint inhibitors can prompt the immune system to attack heart tissue. Details were published Feb. 20, 2026, in the Journal of Experimental Medicine. In about 2% of all cancer patients receiving ICIs, the treatments can cause myocarditis—an inflammation of heart muscle—and about half of these patients die from this complication, even if they survive their cancer.
Immune checkpoint inhibitors work by cutting off signals from “checkpoint” proteins that cancer cells use to hide from the immune system. This allows the body’s T cells to recognize and destroy tumor cells. Since 2011, when the first drug, Yervoy, was approved in the U.S. for treating metastatic melanoma, this form of treatment has revolutionized outcomes for many types of cancer.
To better understand the complication, the research team engineered a new mouse model that accurately mimics immune checkpoint inhibitor-induced myocarditis. In a series of advanced experiments, the team pinpointed a key driver of the complication: CD8 T cell-derived tumor necrosis factor (TNF).
The team found that this complication from checkpoint inhibitors is not caused by tumors exhausting the body’s cancer-specific T cells, but rather through causing new production of “autoreactive” T cells that see healthy cardiac muscle cells as targets in addition to cancer cells. In mice, blocking TNF signaling specifically through the TNFR2 gene product prevented the inflammatory cycle from starting in the heart.
The study said checkpoint inhibitors allow TNF signaling to trigger CD8 T-cells that are specific to antigens on cardiac myocytes, which in turn leads to life-threatening arrythmias. The researchers used a targeted TNF blockade method to prevent this cycle in mouse models and said that, if the results can be replicated in humans, TNF blockade should prevent cardiac toxicity without compromising the anti-tumor benefits of ICIs.
More research is needed to determine if a narrowly focused TNF inhibitor would be safe for human use, and how long a patient might need to take such a drug. TNFR2-specific antibodies remain in development stages. The team also wants to determine whether similar approaches can also prevent immune-related adverse events affecting other organs.